DK3034512T3 - En proces til fremstilling af jern(III)-kasein-N-acetyl-aspartylerede komplekser og anvendelse deraf i farmaceutiske sammensætninger - Google Patents

En proces til fremstilling af jern(III)-kasein-N-acetyl-aspartylerede komplekser og anvendelse deraf i farmaceutiske sammensætninger Download PDF

Info

Publication number
DK3034512T3
DK3034512T3 DK14386034.4T DK14386034T DK3034512T3 DK 3034512 T3 DK3034512 T3 DK 3034512T3 DK 14386034 T DK14386034 T DK 14386034T DK 3034512 T3 DK3034512 T3 DK 3034512T3
Authority
DK
Denmark
Prior art keywords
acetyl
casein
iron
aspartylated
solution
Prior art date
Application number
DK14386034.4T
Other languages
English (en)
Inventor
Ioulia Tseti
Original Assignee
Ioulia Tseti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ioulia Tseti filed Critical Ioulia Tseti
Application granted granted Critical
Publication of DK3034512T3 publication Critical patent/DK3034512T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732Casein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (6)

1. Proces til fremstillingen af jern(III)-kompleks med N-acetyl-L-aspartyleret kasein, omfattende trinnene: (a) at reagere kasein med N-acetyl-L-aspartylchlorid, for at danne N-acetyl-L-aspartyleret kasein, (b) efterfølgende at reagere den N-acetyl-L-aspartylerede kasein med jern(III)chlorid; og (c) at opnå jern(III)-komplekset med N-acetyl-L-aspartyleret kasein.
2. Processen ifølge krav 1, hvor den anvendte kasein er kasein af levnedsmiddelkvalitet.
3. Processen ifølge krav 1, hvor trin (a) omfatter at tilvejebringe en opløsning af kasein, og hvor tilføjelse af N-acetyl-L-aspartylchlorid til kaseinopløsningen udføres ved en pH på mellem 6 og 9.
4. Processen ifølge krav 1, hvor N-acetyl-L-aspartylchloridet fremstilles in situ, fortrinsvis under anvendelse af klorerende reagenser valgt fra gruppen bestående af thionyl chlorid (SOCI2), phosphorpentachlorid (PCI5), phosphortrichlorid (PCb), carbontetrachlorid (CCU), oxalylchlorid (COCI)2, phosphorylchlorid (POCI3), 2-chlor-l,3-bis(methoxycarbonyl)guanidin (Palau'Chlor), cyanurchlorid og N-chlorsuccinimid.
5. Processen ifølge krav 1, hvor jern(III)-komplekset med N-acetyl-L-aspartyleret kasein opnået i trin (c) klares, før det sendes til tørring eller sprøjtetørring eller frysetørring.
6. Proces til fremstilling af en farmaceutisk sammensætning omfattende et jern(III)-kompleks med N-acetyl-L-aspartyleret kasein af levnedsmiddelkvalitet, hvilken proces omfatter processen ifølge et hvilket som helst af kravene 1-5 og at kombinere jern(III)-komplekset med N-acetyl-L-aspartyleret kasein af levnedsmiddelkvalitet med farmaceutiske excipienser, i særdeleshed valgt fra fortyndingsmidler og konserveringsmidler.
DK14386034.4T 2014-12-19 2014-12-19 En proces til fremstilling af jern(III)-kasein-N-acetyl-aspartylerede komplekser og anvendelse deraf i farmaceutiske sammensætninger DK3034512T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14386034.4A EP3034512B1 (en) 2014-12-19 2014-12-19 A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DK3034512T3 true DK3034512T3 (da) 2018-01-15

Family

ID=52354737

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14386034.4T DK3034512T3 (da) 2014-12-19 2014-12-19 En proces til fremstilling af jern(III)-kasein-N-acetyl-aspartylerede komplekser og anvendelse deraf i farmaceutiske sammensætninger

Country Status (29)

Country Link
US (1) US20170340747A1 (da)
EP (1) EP3034512B1 (da)
AP (1) AP2017009801A0 (da)
AU (1) AU2015365885B2 (da)
BR (1) BR112017006621B1 (da)
CA (1) CA2959226C (da)
CL (1) CL2017001611A1 (da)
CO (1) CO2017003313A2 (da)
CY (1) CY1120037T1 (da)
DK (1) DK3034512T3 (da)
EA (1) EA031968B1 (da)
ES (1) ES2655238T3 (da)
GE (1) GEP20207081B (da)
HR (1) HRP20171965T1 (da)
HU (1) HUE035302T2 (da)
IL (1) IL251449B (da)
LT (1) LT3034512T (da)
MX (1) MX2017008100A (da)
MY (1) MY185391A (da)
NO (1) NO3034512T3 (da)
PE (1) PE20180660A1 (da)
PH (1) PH12017500391B1 (da)
PL (1) PL3034512T3 (da)
PT (1) PT3034512T (da)
RS (1) RS56714B1 (da)
SA (1) SA517381261B1 (da)
SG (1) SG11201702593TA (da)
SI (1) SI3034512T1 (da)
WO (1) WO2016096203A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1009589B (el) * 2018-04-05 2019-09-11 Ιουλια Κλεωνος Τσετη Φαρμακευτικο σκευασμα για την αντιμετωπιση της αναιμιας, σε καταλληλο περιεκτη, που διατηρει στεγανα διαχωρισμενα μεταξυ τους τα δραστικα συστατικα: συμπλοκο του τρισθενους σιδηρου με ν-ακετυλο-l-ασπαρτικη καζεϊνη και πενταϋδρικο φυλλινικο ασβεστιο
CN116655512A (zh) * 2023-05-31 2023-08-29 江苏阿尔法药业股份有限公司 一种卡托普利的制备工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB910321A (en) 1960-02-25 1962-11-14 Olivier Paul Gaudin Improvements in and relating to a process for preparing ferrous salts of aspartic acid and medicines containing these salts
IT1150213B (it) 1982-03-02 1986-12-10 Italfarmaco Spa Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche
IT1207996B (it) 1986-03-18 1989-06-01 Magis Farmaceutici Composti contenenti ferro biodisponibile, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
GB9621273D0 (en) 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method
IT1297022B1 (it) 1997-12-24 1999-08-03 Chemi Spa Complesso di ferro-succinilcaseina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono
ITMO20040200A1 (it) 2004-07-29 2004-10-29 Biofer Spa Processo per la produzione di complessi ferro succinilcaseina e ferro casein acetil aspartilato e loro utilizzato nelle relative composizioni farmaceutiche.

Also Published As

Publication number Publication date
HRP20171965T1 (hr) 2018-02-23
ES2655238T3 (es) 2018-02-19
CA2959226C (en) 2018-10-09
WO2016096203A1 (en) 2016-06-23
EP3034512B1 (en) 2017-12-06
MY185391A (en) 2021-05-17
PH12017500391A1 (en) 2017-07-17
SG11201702593TA (en) 2017-04-27
RS56714B1 (sr) 2018-03-30
IL251449B (en) 2019-02-28
IL251449A0 (en) 2017-05-29
AP2017009801A0 (en) 2017-03-31
SA517381261B1 (ar) 2017-12-20
LT3034512T (lt) 2018-01-25
AU2015365885B2 (en) 2018-11-15
CL2017001611A1 (es) 2018-01-26
EA031968B1 (ru) 2019-03-29
NO3034512T3 (da) 2018-05-05
US20170340747A1 (en) 2017-11-30
HUE035302T2 (en) 2018-05-02
PE20180660A1 (es) 2018-04-17
EP3034512A1 (en) 2016-06-22
GEP20207081B (en) 2020-03-25
PL3034512T3 (pl) 2018-03-30
PH12017500391B1 (en) 2017-07-17
BR112017006621B1 (pt) 2023-11-07
CO2017003313A2 (es) 2017-07-28
EA201790902A1 (ru) 2017-10-31
SI3034512T1 (en) 2018-04-30
PT3034512T (pt) 2018-01-11
AU2015365885A1 (en) 2017-03-16
CY1120037T1 (el) 2018-12-12
BR112017006621A2 (pt) 2017-12-19
CA2959226A1 (en) 2016-06-23
MX2017008100A (es) 2017-10-31

Similar Documents

Publication Publication Date Title
RU2408601C2 (ru) Способ получения железосодержащего сукцинилированного казеина
DK159824B (da) Analogifremgangsmaade til fremstilling af succinylferroproteiner
DK3034512T3 (da) En proces til fremstilling af jern(III)-kasein-N-acetyl-aspartylerede komplekser og anvendelse deraf i farmaceutiske sammensætninger
KR100563361B1 (ko) 페로-숙신일카제인 착화물, 그 제조방법 및 이를 함유하는 약제조성무류
OA18236A (en) A process for producing iron (III) casein Nacetyl-aspartylated complexes and use thereof in pharmaceutical compositions.
KR900003695B1 (ko) 글로빈 또는 아세틸글로빈의 철-유도체의 제조방법
JP2660906B2 (ja) ウニ由来カルシウムの製造方法ならびにこの製造方法によって得られる易吸収性カルシウムを含有する組成物
WO1996038058A1 (fr) Composition contenant du calcium facilement absorbable et son procede de fabrication
JPH0947253A (ja) 易吸収性カルシウムを含有する組成物およびその製造 方法
KR970008109B1 (ko) 생물학적으로 매우 유용한 형태의 철을 함유한 단백질 유도체, 그의 제조방법 및 이 화합물을 함유하는 제약 조성물
KR100513011B1 (ko) 가용성 칼슘-핵산물질 복합체 및 그 제조방법
PL104763B1 (pl) Sposob wytwarzania nowej postaci krystalicznej soli sodowej kwasu 7-cyjanoacetyloamino-3-acetoksymetylocefem-3-karboksylowego-4
JP2002119218A (ja) 低イソフラボン大豆蛋白及びその製造法
JP2014233266A (ja) 米糠タンパク質を含む糖尿病性腎症進展抑制用栄養組成物